Navigation Links
AIDS Drugs Going Strong and Steady

According to the Professor Matthias Egger, of the University of Bern in Switzerland, AIDS drugs are still effective and patients suffer from fewer side effects// due the drug.

There is also decreased development of resistance due to the drug. It been ten years since the antiretroviral (ARVs) have been introduced in the market with no major complication and drawbacks. Scientists say that the combinations of drugs reduce mortality and progression to AIDS by about 80-90 % but tuberculosis (TB) has become a deadly co-infection among AIDS patients. The study results were based on the analysis of more than 22,200 HIV positive people in Europe and North America who started treatment between 1995 and 2003.

It was published in the Lancet medical journal with the help of the Antiretroviral Therapy Cohort Collaboration. According to the lead researcher Bernard Hirschel at the Geneva University Hospital in Switzerland, the only effective way to reduce the incidence of AIDS is to start the treatment at an earlier stage when the CD4 cell count dropped below 350 or if the individual showed symptoms of illness.


'"/>




Page: 1

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: AIDS Drugs Going Strong and Steady

(Date:12/4/2009)..., , PEMBROKE, Bermuda, Dec. 4 /PRNew... Holdings, Ltd (NYSE: AWH ) today announced that...ficer, and Jack Sennott, Executive Vice,President ...enting at the 2009,Goldman Sachs U.S. Financial Se...Conference Center in New York City on Tuesday, Dec...
(Date:12/4/2009)..., , ANAHEIM, Calif., Dec. 4 /PRNewswire/...scent Healthcare, was selected as a finalist for t...forming Crescent,s business with the power of clou...ased on their innovative usage of Salesforce CRM o... customer success to their sales, marketing, partn...
(Date:12/4/2009)..., Working with mice, scientists at Johns Hopkins...ave shown that a protein made by a gene called "Tw...ately distinguish stem cells that drive aggressive...r cells. , Building on recent work suggesting th...in breast tumors that drives breast cancer, scient...
(Date:12/4/2009)...Outcomes same whether procedure done immediately o... Dec. 4 (HealthDay News) -- Timing of surgical rep...juries may not affect patient outcome, a new study...esult from traumatic knee dislocations that can oc...s. The optimal time to perform surgery to repair t...
(Date:12/4/2009)...Research and surveillance urged for at-risk patien...ews) -- Some childhood cancers, particularly Ewing... the risk of late recurrence, U.S. researchers hav... 12,795 five-year survivors of the most common ped...Cancer Survivor Study. , The researchers found ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
... screenwriters have a lower life expectancy than n...ainly improve your health and longevity - but it d..., Texas, reveal the health risks of winning an Aca...4 years than mere nominees. This is despite having...
...rong connection between celiac disease and diabete...eliac disease in people with type 1 diabetes is ab.... Doctors have uncovered a new finding for diabeti...tion to gluten. Both CD and diabetes are common ch...
...ciation for Continence, a new study shows early in...evalence of incontinence. Incontinence is loss of ...any conditions can cause incontinence,// including... ...
...t they may one day be able to reverse some cases o...indings from an animal study that show infertile m...on to produce offspring.// According to resea...f those are a result of problems with sperm produc...
...th Care System, obese adults who undergo 'stomach ...covered 'hunger hormone' than either normal-weight... Dr. David E. Cumming from the Puget Sound Health...oblems such as type 2 diabetes and other chronic d...
... play a role in reducing the number of childhood d...who tested three different methods of zinc adminis...zinc reduced the risk of prolonged diarrhea// defi...er or the child's caregiver. More than 3 mill...
Other Medicine News:Health News:Decrease of 'Hunger Hormone' after Obesity Surgery 2
(Date:12/4/2009)...., Dec. 4 AstraZeneca (N...Drug Administration (FDA) has approved once-daily ...elease Tablets as adjunctive (add-on) treatment to...isorder (MDD). SEROQUEL XR is the only medication ...or depressive disorder as adjunctive therapy and a...
(Date:12/3/2009)...Dec. 3 A genetic variati...g a potentially life-threatening blood disorder if...emicals is one of several medical discoveries scie...ics (NYSE: DGX ) will present during the 51st Am...and Exposition, December 5-8, 2009, in New Orleans...
(Date:12/3/2009)...el., Dec. 3 ParagonRx, a Delaware-...management and optimal medication use, will host a...raft guidance on REMS - Risk Evaluation Mitigation... lifecycle management. Dr. Gary Slatko, chief med...d risk management programs, will lead the one-hour...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3No Increase in Brain Tumors Seen From Cell Phones 62563 1No Increase in Brain Tumors Seen From Cell Phones 62563 2No Increase in Brain Tumors Seen From Cell Phones 62563 3RN SuperUnion Founding Convention Opens Monday 62559 1RN SuperUnion Founding Convention Opens Monday 62559 2Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 1Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 2Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 3
...the human vaccine business unit of Schering-Plough...it has reached an important milestone with the ini... program for SCH 900795, a new intranasal Live Att...al use. , , The candidate vaccine is composed of ... by the World Health Organization (WHO) for season...
...esented at USCAP Meeting , , SOUTH SAN FRANCISCO,...sdaq: RIGL ) today announced the enrollment of t...al trial of R788 (fostamatinib disodium) in patien...ymphoma (PTCL). The clinical trial,s primary obje... bio-available Syk kinase inhibitor, in patients s...
Other Medicine Technology:Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 2Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 3Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3
...YDON is a long-pulsed Nd:YAG laser system with a w...deep-lying, superficial as well as red and blue ve...pilation in patients with darker skin types (1 to ...vement of skin texture. The handpieces special des...
...he UroVysion Bladder Cancer Kit (UroVysion Kit) is...7, 17, and loss of the 9p21 locus via fluorescence...rom persons with hematuria suspected of having bla...tended for use, in conjunction with and not in lie...
The BTA TRAK® Assay
ARION Long-Pulsed Alexandrite Laser System
Medicine Products: